Clinical trials: Cytomegalovirus
Lung Transplant; Complications
CMV Immunity Monitoring in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant.
- Trial name
- NCT05708755
- Testing
- Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NYU Langone Health
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant.
- Trial name
- HELIOS (NCT01877655)
- Testing
- ASP0113
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 514 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding.
- Trial name
- NCT00002373
- Testing
- Maribavir
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Glaxo Wellcome
Cytomegalovirus Disease
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
To compare the efficacy of oral brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a…
- Trial name
- SUSTAIN (NCT02439970)
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
CMV, CMV Infection
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
- Conditions
- CMV, CMV Infection, Hematopoietic Cell Transplant
- Trial name
- NCT04017962
- Testing
- Letermovir Pill, blood draw
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir
To examine the safety and tolerance of the administration of ganciclovir and foscarnet given together or alternately; to determine the interactive pharmacokinetics (blood level) profile of long-term combined and alternating…
- Trial name
- NCT00000970
- Testing
- Foscarnet sodium, Ganciclovir
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transplantation, Infection
Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.
- Conditions
- Transplantation, Infection, Cytomegalovirus Infections
- Trial name
- NCT00170170
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Mayo Clinic
CMV Infection, Hematopoietic Stem Cell Transplantation
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
- Trial name
- NCT06021210
- Testing
- Letermovir Pill
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
This phase II trial studies how well donor cytomegalovirus-specific cytotoxic T-lymphocytes work in treating patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy.
- Conditions
- Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT02210078
- Testing
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Dialysis, Healthy Subjects
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
The purpose of the study is to determine whether ASP0113 (a CMV deoxyribonucleic acid [DNA] vaccine) can be detected in plasma after intramuscular (IM) injections, and to determine whether CMV-seropositive healthy volunteers…
- Conditions
- Dialysis, Healthy Subjects, Cytomegalovirus Infection
- Trial name
- NCT02103426
- Testing
- ASP0113
- Where
- 4 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Liver Transplantation
Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
Null Hypothesis: There is no significant difference in the incidence of CMV infection when using oral valganciclovir or ganciclovir as prophylactic anti-viral therapy.
- Trial name
- NCT00364052
- Testing
- oral Valganciclovir vs oral Ganciclovir
- Volunteers
- 200 people
- Sponsor
- Oregon Health and Science University
Cytomegalovirus Infection
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Cytomegalovirus (CMV) infection is known to cause hearing loss and mental retardation. The purpose of this study is to compare a 6-week course to a 6-month course of the drug valganciclovir in babies born with CMV to assess the…
- Trial name
- NCT00466817
- Testing
- Valganciclovir
- Where
- 48 sites in United States, United Kingdom
- Volunteers
- 109 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Prospective Study of HIV Infection in Hemophiliacs
To examine mechanisms of individual differences in the progression of HIV infection in hemophiliacs.
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections, Blood Disease, Hemophilia A
- Trial name
- NCT00005309
- Sponsor
- Bloodworks
Graft-versus-host-disease, CMV
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.
- Trial name
- NCT05969743
- Testing
- Letermovir
- Volunteers
- 42 people
- Sponsor
- Rabin Medical Center
Glioblastoma Multiforme, GBM
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
Patients have a type of brain cancer called glioblastoma multiforme. Because most GBMs come back after standard therapy, patients are being asked to volunteer to take part in a research study using special immune cells.
- Conditions
- Glioblastoma Multiforme, GBM, Brain Cancer
- Trial name
- COGLI (NCT01205334)
- Testing
- Autologous CMV-specific CTL
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baylor College of Medicine
Cytomegalovirus Infection
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
This is a phase I safety, PK and food effect study of the CMV drug. In part 1 of the study, subjects will receive one of four dosage strengths of MBX-400 (100 mg once daily, 350 mg once daily; 750 mg once daily; and 1000 once…
- Trial name
- NCT02454699
- Testing
- MBX400
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, Heart Transplantation
Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)
Context Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. Most of available treatment display adverse effects that limit their use.
- Conditions
- Cytomegalovirus Infections, Heart Transplantation, Kidney Transplantation, Lung Transplantation
- Trial name
- QUANTIFOT (NCT06341543)
- Testing
- Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes)., Communication of the result of the QF-CMV to the clinician in charge
- Where
- France
- Volunteers
- 288 people
- Sponsor
- University Hospital, Grenoble
Hearing Loss, Cytomegalovirus
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
This study will look at the feasibility and acceptability of testing newborn babies who are referred after their newborn hearing screen for an infection called congenital Cytomegalovirus (cCMV).
- Trial name
- BEST (NCT01162330)
- Testing
- Screening urine and saliva tests for congenital Cytomegalovirus
- Where
- United Kingdom
- Volunteers
- 411 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Cytomegalovirus Infections
Breakthrough CMV Lung Transplant -Multicentre
Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplantation leading to direct and indirect effects that can result in life threatening complications.
- Trial name
- NCT04439916
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Cytomegalovirus Retinitis
Deep Learning-based System and AIDS-related Cytomegalovirus Retinitis
Ophthalmological screening for cytomegalovirus retinitis (CMVR) for HIV/AIDS patients is important. However, the manual screening with fundus imaging is laborious and subjective.
- Trial name
- NCT04831333
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Kuifang Du